$SLBT News

SL Science Holding Limited Reports First Half 2026 Financial Results

SL Science Holding H1 Sales $1.387M Up From $1.129M YoY

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

SL Science: A $1.15 Billion Valuation Built On Preclinical Promises

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

SL Science Highlighted The Filing Of A New Drug Master File With The U.S. FDA Covering Exosomes Derived From Gamma Delta T Cells

SL Science Holding (SLBT) Stock May Be Fully Priced Even After A 74% Fall

SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

SL Science Announces Publication Of Peer-Reviewed Article In 'Biomedicines' Outlining A Rigorous Development Framework For γδ T Cell Therapy In Glioblastoma

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

SL Science Presents Benefits Of Gamma Delta T Cells In Eliminating Glioblastoma In Preclinical Studies At The 2026 World Congress Of Basic And Clinical Pharmacology

SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma

SL Science Submits Orphan Drug Designation Request To FDA For Gamma Delta T Cell Therapy Product, Vdelta2+ Gamma Delta T Cells, For Treatment Of Glioblastoma Multiforme

SL Science Holding Limited Reports Full Year 2025 Financial Results

SL Science Holding shares are trading higher amid volatility following the SPAC combination of SL Bio and Horizon Space Acquisition II and the company's subsequent Nasdaq listing.